| A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma (NCT01677390) | Seagen Inc. | 2012-08-01 |
| CRLX101 Plus Bevacizumab in Advanced RCC (NCT01625936) | Abramson Cancer Center at Penn Medicine | 2012-06-01 |
| Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) (NCT01613846) | Technical University of Munich | 2012-05-01 |
| Sunitinib Drug Levels and Outcomes in Kidney Cancer (NCT01711268) | Western Sydney Local Health District | 2012-05-01 |
| To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors (NCT02410174) | Beth Israel Medical Center | 2012-05-01 |
| Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma (NCT01598038) | Centre Francois Baclesse | 2012-04-01 |
| Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment (NCT01473043) | Pfizer | 2012-03-01 |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (NCT01472081) | Bristol-Myers Squibb | 2012-02-09 |
| TRACERx Renal CAPTURE Sub-study (NCT03226886) | Royal Marsden NHS Foundation Trust | 2012-02-05 |
| Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma (NCT02030717) | Umeå University | 2012-02-01 |
| AMG 172 First in Human Study in Patients With Kidney Cancer (NCT01497821) | Amgen | 2012-01-01 |
| PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine (NCT01441765) | Beth Israel Deaconess Medical Center | 2011-11-01 |
| Caphosol in Oral Mucositis Due to Targeted Therapy (NCT01265810) | Impaqtt Foundation | 2011-11-01 |
| Brivanib Metastatic Renal Cell Carcinoma (NCT01253668) | Abramson Cancer Center at Penn Medicine | 2011-11-01 |
| Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy (NCT01442090) | Genentech, Inc. | 2011-10-01 |
| PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma (NCT01502228) | Indiana University | 2011-10-01 |
| Phase I Biomarker Study (BMS-936558) (NCT01358721) | Bristol-Myers Squibb | 2011-09-23 |
| A Rollover Protocol for Subjects Previously Treated With AGS-003 (NCT01482949) | Argos Therapeutics | 2011-09-01 |
| Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma (NCT01283048) | Toni Choueiri, MD | 2011-09-01 |
| Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) (NCT01399918) | Memorial Sloan Kettering Cancer Center | 2011-07-01 |
| Safety Study of MGA271 in Refractory Cancer (NCT01391143) | MacroGenics | 2011-07-01 |
| A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) (NCT01014065) | AHS Cancer Control Alberta | 2011-07-01 |
| Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma (NCT01762150) | Peking University Cancer Hospital & Institute | 2011-06-01 |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma (NCT01361113) | UNC Lineberger Comprehensive Cancer Center | 2011-06-01 |
| BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) (NCT01354431) | Bristol-Myers Squibb | 2011-05-31 |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin (NCT01466504) | Dartmouth-Hitchcock Medical Center | 2011-05-01 |
| Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. (NCT01339962) | Pfizer | 2011-04-01 |
| Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (NCT01331135) | Emory University | 2011-04-01 |
| HYPAZ: Hypertension Induced by Pazopanib (NCT01392352) | Cambridge University Hospitals NHS Foundation Trust | 2011-04-01 |
| Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 (NCT01566747) | Cancer Trials Ireland | 2011-03-01 |
| Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble (NCT01224288) | M.D. Anderson Cancer Center | 2011-01-05 |
| Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma (NCT01240005) | Qingdao University | 2011-01-01 |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma (NCT01297244) | AVEO Pharmaceuticals, Inc. | 2011-01-01 |
| Association Between Hepatitis C Infection and Renal Cell Carcinoma (NCT01405183) | Henry Ford Health System | 2011-01-01 |
| The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma (NCT01227213) | Radboud University Medical Center | 2010-11-01 |
| Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) (NCT01216371) | Association of Urologic Oncology (AUO) | 2010-10-01 |
| Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma (NCT01070186) | Jonsson Comprehensive Cancer Center | 2010-10-01 |
| Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma (NCT01144169) | University of Pittsburgh | 2010-10-01 |
| Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors (NCT02850809) | University Hospital, Bordeaux | 2010-10-01 |
| Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (NCT01210482) | Pfizer | 2010-08-24 |
| A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer (NCT01114230) | Astellas Pharma Inc | 2010-08-01 |
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors (NCT01176500) | National Cancer Institute (NCI) | 2010-07-28 |
| Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma (NCT01173445) | University of Kansas | 2010-07-01 |
| Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma (NCT00953446) | Beth Israel Deaconess Medical Center | 2010-06-15 |
| Cancer in Patients With Gabapentin (GPRD) (NCT01236053) | GlaxoSmithKline | 2010-06-01 |
| Dendritic Cell Vaccination for Patients with Solid Tumors (NCT01291420) | University Hospital, Antwerp | 2010-05-03 |
| Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) (NCT01138124) | GlaxoSmithKline | 2010-03-01 |
| BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma (NCT01034631) | Hoosier Cancer Research Network | 2010-01-01 |
| Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence (NCT01147536) | Agenus Inc. | 2010-01-01 |
| Exercise for Patients With Renal Cell Cancer Receiving Sunitinib (NCT00869011) | Charite University, Berlin, Germany | 2009-12-01 |
| A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. (NCT01206764) | Novartis Pharmaceuticals | 2009-11-11 |
| Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (NCT00903175) | Novartis Pharmaceuticals | 2009-10-01 |
| Efficacy of Ultrasound Contrast Agent to Assess Renal Masses (NCT01062178) | University Health Network, Toronto | 2009-10-01 |
| Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma (NCT00975806) | Celgene | 2009-09-01 |
| Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland (NCT00980213) | Pirkko-Liisa Kellokumpu-Lehtinen | 2009-09-01 |
| Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma (NCT00556205) | Massachusetts General Hospital | 2009-09-01 |
| Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (NCT00970970) | University Medical Center Groningen | 2009-09-01 |
| A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma (NCT01063998) | Jason Hafron | 2009-09-01 |
| A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy (NCT02264548) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2009-07-01 |
| Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT00944905) | Bristol-Myers Squibb | 2009-07-01 |
| Follow-up After Metastasectomy in Patients With Kidney Cancer (NCT00918775) | M.D. Anderson Cancer Center | 2009-06-09 |
| Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection (NCT00918281) | GE Healthcare | 2009-06-01 |
| A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma (NCT00934440) | University of Kansas Medical Center | 2009-06-01 |
| Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma (NCT00876382) | SCRI Development Innovations, LLC | 2009-05-01 |
| An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 (NCT00884520) | Siemens Molecular Imaging | 2009-04-01 |
| Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer (NCT01026337) | Abramson Cancer Center at Penn Medicine | 2009-04-01 |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma (NCT00782275) | Beth Israel Deaconess Medical Center | 2009-04-01 |
| A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies (NCT00923520) | National Cancer Institute (NCI) | 2009-03-25 |
| DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma (NCT00862303) | Fuzhou General Hospital | 2009-03-01 |
| Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (NCT00827359) | Beth Israel Deaconess Medical Center | 2009-03-01 |
| Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent (NCT00836745) | Pfizer | 2009-03-01 |
| Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer (NCT00923130) | National Cancer Institute (NCI) | 2009-01-07 |
| VEGF Imaging in Renal Cell Carcinoma (NCT00831857) | University Medical Center Groningen | 2009-01-01 |
| RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) (NCT00830895) | Seoul National University Hospital | 2009-01-01 |
| Novel Prognostic Markers in Renal Cancer (NCT01002937) | Royal Marsden NHS Foundation Trust | 2008-12-01 |
| A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma (NCT01041482) | Chinese Academy of Medical Sciences | 2008-11-01 |
| Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma (NCT01254838) | Iwate Medical University | 2008-11-01 |
| A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (NCT00730639) | Bristol-Myers Squibb | 2008-10-30 |
| A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma (NCT00788060) | Daniel George, MD | 2008-10-01 |
| Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor (NCT00979381) | Radboud University Medical Center | 2008-10-01 |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors (NCT00777504) | Radboud University Medical Center | 2008-10-01 |
| Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma (NCT00731211) | SCRI Development Innovations, LLC | 2008-09-01 |
| Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) (NCT00749320) | Beth Israel Deaconess Medical Center | 2008-09-01 |
| Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma (NCT01404104) | St. Joseph's Healthcare Hamilton | 2008-09-01 |
| Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma (NCT01482520) | Samsung Medical Center | 2008-08-01 |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) (NCT00753415) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Comparison Between Partial Nephrectomy and Ablation for Renal Tumor (NCT03094949) | Chinese PLA General Hospital | 2008-07-01 |
| Genetic Susceptibility to Kidney Cancer (NCT00854022) | Baylor College of Medicine | 2008-07-01 |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) (NCT00715442) | M.D. Anderson Cancer Center | 2008-06-24 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (NCT00625456) | Jennerex Biotherapeutics | 2008-06-01 |
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00684996) | National Cancer Institute (NCI) | 2008-06-01 |
| Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (NCT00631371) | Pfizer | 2008-04-01 |
| Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens (NCT00718367) | National University Hospital, Singapore | 2008-03-01 |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer (NCT00923845) | National Cancer Institute (NCI) | 2008-03-01 |
| Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) (NCT00672178) | Duke University | 2008-03-01 |
| Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody (NCT00606632) | Heidelberg Pharma AG | 2008-03-01 |
| Phase I Study of Vorinostat and Sorafenib in Advanced Cancer (NCT00635791) | University of Colorado, Denver | 2008-03-01 |
| Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors (NCT00610389) | Clinica Universidad de Navarra, Universidad de Navarra | 2008-02-01 |
| LBH589 Treatment for Refractory Clear Cell Renal Carcinoma (NCT00550277) | SCRI Development Innovations, LLC | 2008-01-01 |
| Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (NCT00557830) | Accelerated Community Oncology Research Network | 2008-01-01 |